{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:51:59Z","timestamp":1791179519403,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.maturitas.2014.05.002","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T13:05:44Z","timestamp":1399640744000},"page":"252-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Genetic testing and familial implications in breast-ovarian cancer families"],"prefix":"10.1016","volume":"78","author":[{"given":"Jan C.","family":"Oosterwijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian J.","family":"Mourits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geertruida H.","family":"de Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2014.05.002_bib0005","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1002\/ijc.26315","article-title":"Progress against cancer in the Netherlands since the late 1980: an epidemiological evaluation","volume":"12","author":"Karim-Kos","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/bjc.2013.730","article-title":"BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface","volume":"2","author":"Lee","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0015","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.bjc.6603306","article-title":"Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of \u2018easy to apply\u2019 probability models","volume":"6","author":"Bodmer","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0020","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jmg.2009.067850","article-title":"Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing","volume":"12","author":"Evans","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0025","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO.2013.50.6055","article-title":"Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study","volume":"12","author":"Daniels","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/jmg.2007.056556","article-title":"Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics","volume":"7","author":"Antoniou","year":"2008","journal-title":"J Med Genet"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10689-012-9584-9","article-title":"10 rare tumors that warrant a genetics referral","volume":"1","author":"Banks","year":"2013","journal-title":"Fam Cancer"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1399-0004.2009.01309.x","article-title":"Beyond BRCA1 and BRCA2 wild-type breast and\/or ovarian cancer families: germline mutations in TP53 and PTEN","volume":"2","author":"Blanco","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12687-011-0042-4","article-title":"Genetic testing for familial\/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany","volume":"2","author":"Gadzicki","year":"2011","journal-title":"J Community Genet"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12687-013-0173-x","article-title":"Cancer risk communication, predictive testing and management in France, Germany, the Netherlands and the UK: general practitioners\u2019 and breast surgeons\u2019 current practice and preferred practice responsibilities","volume":"1","author":"Nippert","year":"2014","journal-title":"J Community Genet"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0055","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1245\/s10434-013-3205-1","article-title":"Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort","volume":"10","author":"Greenup","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0060","doi-asserted-by":"crossref","first-page":"vi31","DOI":"10.1093\/annonc\/mdr373","article-title":"BRCA in breast cancer: ESMO Clinical Practice Guidelines","author":"Balmana","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0065","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/humu.20340","article-title":"A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting","volume":"7","author":"van der Hout","year":"2006","journal-title":"Hum Mutat"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0070","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jnci\/djq443","article-title":"Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations","volume":"24","author":"Metcalfe","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0075","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1158\/0008-5472.CAN-10-1907","article-title":"Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction","volume":"23","author":"Antoniou","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0080","doi-asserted-by":"crossref","first-page":"e1003284","DOI":"10.1371\/journal.pgen.1003284","article-title":"Evidence of gene\u2013environment interactions between common breast cancer susceptibility loci and established environmental risk factors","volume":"3","author":"Nickels","year":"2013","journal-title":"PLoS Genet"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0085","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/jmedgenet-2013-101974","article-title":"Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations","volume":"2","author":"Brohet","year":"2014","journal-title":"J Med Genet"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0090","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajmg.a.20374","article-title":"Impact of BRCA1\/2 testing and disclosure of a positive test result on women affected and unaffected with breast or ovarian cancer","volume":"4","author":"van Roosmalen","year":"2004","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0095","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1001\/jama.2011.678","article-title":"Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer","volume":"21","author":"Tung","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0100","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"11","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0105","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10549-010-0805-3","article-title":"Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age","volume":"3","author":"van der Kolk","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0110","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/bjc.2011.120","article-title":"Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"9","author":"Metcalfe","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0115","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/bcr3369","article-title":"The risk of contralateral breast cancer in patients from BRCA1\/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study","volume":"6","author":"Rhiem","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0120","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cncr.27842","article-title":"Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer","volume":"7","author":"Domchek","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0125","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/cncr.27839","article-title":"The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1\/BRCA2 mutation carriers: implications for counseling","volume":"5","author":"Vencken","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2004.09.039","article-title":"The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers","volume":"1","author":"Metcalfe","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ygyno.2009.06.012","article-title":"Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers","volume":"1","author":"Vicus","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.maturitas.2011.10.008","article-title":"Model of care for women at increased risk of breast and ovarian cancer","volume":"1","author":"De Bock","year":"2012","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0145","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.breast.2013.04.006","article-title":"Practical aspects of genetic counseling in breast cancer: lights and shadows","volume":"4","author":"Christinat","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0150","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","article-title":"Survival analysis of cancer risk reduction strategies for BRCA1\/2 mutation carriers","volume":"2","author":"Kurian","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0155","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1200\/JCO.2011.38.6060","article-title":"Online tool to guide decisions for BRCA1\/2 mutation carriers","volume":"5","author":"Kurian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0160","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2014.02.039","article-title":"PARP inhibitors in ovarian cancer: current status and future promise","volume":"133","author":"Liu","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0165","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.breast.2013.07.045","article-title":"Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies","volume":"5","author":"Francken","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0170","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/bjc.2013.805","article-title":"Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial","volume":"4","author":"Wevers","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0175","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.1188\/12.ONF.E101-E111","article-title":"Getting to the point: what women newly diagnosed with breast cancer want to know about treatment-focused genetic testing","volume":"2","author":"Meiser","year":"2012","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0180","first-page":"2949","article-title":"Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer","volume":"11","author":"Zilliacus","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0185","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10897-011-9475-5","article-title":"Psychological distress with direct-to-consumer genetic testing: a case report of an unexpected BRCA positive test result","volume":"3","author":"Dohany","year":"2012","journal-title":"J Genet Couns"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejmg.2011.03.006","article-title":"Written information to patients in clinical genetics: what's the impact","volume":"3","author":"Cassini","year":"2011","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0195","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10689-013-9636-9","article-title":"Informing family members of individuals with Lynch syndrome: a guideline for clinical geneticists","volume":"2","author":"Menko","year":"2013","journal-title":"Fam Cancer"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0200","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1158\/1055-9965.EPI-13-0316-T","article-title":"Increased rate of phenocopies in all age groups in BRCA1\/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers","volume":"12","author":"Evans","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0205","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10689-013-9644-9","article-title":"Can we test for hereditary cancer at 18 years when we start surveillance at 25? Patient reported outcomes","volume":"4","author":"Sie","year":"2013","journal-title":"Fam Cancer"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0210","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"3","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0215","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"5","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0220","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"5645","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0225","first-page":"194","article-title":"Variation of breast cancer risk among BRCA1\/2 carriers","volume":"2","author":"Begg","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0230","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"11","author":"Mavaddat","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0235","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr2223","article-title":"A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history","volume":"1","author":"Gomez Garcia","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0240","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results","volume":"11","author":"Plon","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0245","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1471-2407-9-211","article-title":"A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants: BRCA1 and BRCA2 as an example","volume":"9","author":"Mohammadi","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0250","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/jmedgenet-2012-101037","article-title":"BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk","volume":"8","author":"Spurdle","year":"2012","journal-title":"J Med Genet"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0255","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1399-0004.2010.01581.x","article-title":"Perceiving cancer-risks and heredity-likelihood in genetic-counseling: how counselees recall and interpret BRCA 1\/2-test results","volume":"3","author":"Vos","year":"2011","journal-title":"Clin Genet"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0260","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1200\/JCO.2012.46.9403","article-title":"Multiplex genetic testing for cancer susceptibility: out on the high wire without a net","volume":"10","author":"Domchek","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0265","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/GIM.0b013e318204cfed","article-title":"Family communication matters: the impact of telling relatives about unclassified variants and uninformative DNA-test results","volume":"4","author":"Vos","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0270","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/1055-9965.EPI-03-0090","article-title":"Risk estimation for healthy women from breast cancer families: new insights and new strategies","volume":"1","author":"van Asperen","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0275","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.bjc.6604830","article-title":"Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation","volume":"2","author":"Metcalfe","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0280","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1251827","article-title":"Two decades after BRCA: setting paradigms in personalized cancer care and prevention","volume":"6178","author":"Couch","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0285","doi-asserted-by":"crossref","DOI":"10.1002\/pon.3537","article-title":"Understanding of BRCA1\/2 genetic tests results: the importance of objective and subjective numeracy","author":"Hanoch","year":"2014","journal-title":"Psychooncology"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0290","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.molonc.2010.04.011","article-title":"Genetic susceptibility to breast cancer","volume":"3","author":"Mavaddat","year":"2010","journal-title":"Mol Oncol"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0295","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2796.2011.02502.x","article-title":"Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers","volume":"4","author":"Barnes","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0300","article-title":"Familial history of ovarian carcinoma: policy","volume":"A2392","author":"de Hullu","year":"2011","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0305","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.53.6607","article-title":"Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment","author":"Kurian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0310","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1200\/JCO.2013.51.4661","article-title":"Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative","volume":"8","author":"Wood","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0315","doi-asserted-by":"crossref","first-page":"646","DOI":"10.5694\/mja13.11218","article-title":"The Angelina Jolie effect","volume":"10","author":"James","year":"2013","journal-title":"Med J Aust"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0320","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1158\/1055-9965.EPI-11-0991","article-title":"Long-term psychosocial outcomes of BRCA1\/BRCA2 testing: differences across affected status and risk-reducing surgery choice","volume":"3","author":"Graves","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.maturitas.2014.05.002_bib0325","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10897-013-9649-4","article-title":"Specific psychosocial issues of individuals undergoing genetic counseling for cancer \u2013 a literature review","volume":"2","author":"Eijzenga","year":"2014","journal-title":"J Genet Couns"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214001546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214001546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:59:49Z","timestamp":1759913989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512214001546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0378512214001546"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.05.002","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic testing and familial implications in breast-ovarian cancer families","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}